

EFFECTIVE DATE: 01|01|2024

POLICY LAST REVIEWED: 10|15|2025

OVERVIEW

It is well established that early detection of colorectal cancer (CRC) reduces disease-related mortality. For patients at average risk for CRC, organizations such as the U.S. Preventive Services Task Force have recommended several options for colon cancer screening. Currently accepted screening options for CRC include colonoscopy or sigmoidoscopy, fecal occult blood testing, and fecal immunochemical testing. However, many individuals do not undergo recommended screening with fecal tests or colonoscopy. A simpler screening blood test for genetic alterations associated with non-familial CRC may have the potential to encourage screening and decrease mortality if associated with increased screening compliance. Genetic testing is also being investigated to guide therapy.

The following tests are addressed in this policy:

- BeScreened™–CRC test (Beacon Biomedical, Inc.) CPT code 0163U
- Colorectal cancer screening; blood-based biomarker HCPCS code G0327
- Gene expression profiling (eg, ColonSentry® by StageZero Life Sciences, Ltd.) Unlisted CPT code
- SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis (eg, ColoVantage® by Enterix, Epi proColon® by Epigenomics) CPT code 81327

MEDICAL CRITERIA

Medicare Advantage Plans and Commercial Products

Unless otherwise noted, for any test filed with an Unlisted CPT code, the medical necessity criteria in the Genetic Testing Services policy would be used. Please see the Related Policies section.

PRIOR AUTHORIZATION

Medicare Advantage Plans and Commercial Products

There is no specific CPT coding for some of the services referenced in this policy. Therefore, an Unlisted CPT code should be used (see Coding Section for details). All Unlisted genetic testing CPT codes require prior authorization to determine what service is being rendered and if the service is covered or not medically necessary. See the Related Policies section.

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products and is obtained via the online tool for participating providers. See the Related Policies section.

POLICY STATEMENT

Medicare Advantage Plans

The following test(s) are covered without a prior authorization requirement:

- Colorectal cancer screening; blood-based biomarker (HCPCS G0327)

The following test(s) are not covered as the evidence is insufficient to determine that the technology results in an improvement in the net health outcomes:

- BeScreened™–CRC test (CPT code 0163U)
- Gene expression profiling (eg, ColonSentry®) (Unlisted CPT code)
- SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis (eg, ColoVantage®, Epi proColon®) (CPT code 81327)

Note: Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all Medicare Advantage Plans policies. Therefore, Medicare Advantage Plans policies may differ from Commercial products. In some instances, benefits for Medicare Advantage Plans may be greater than what is allowed by the CMS.

Commercial Products

The following test(s) are not medically necessary as the evidence is insufficient to determine that the technology results in an improvement in the net health outcomes:

- BeScreened™–CRC test (CPT code 0163U)
- Colorectal cancer screening; blood-based biomarker (HCPCS code G0327)
- Gene expression profiling (eg, ColonSentry®) (Unlisted CPT code)
- SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis (eg, ColoVantage®, Epi proColon®) (CPT code 81327)

Some genetic testing services are not covered and a contract exclusion for any self-funded group that has excluded the expanded coverage of biomarker testing related to the state mandate, **R.I.G.L. §27-19-81** described in the Biomarker Testing Mandate policy. For these groups, a list of which genetic testing services are covered with prior authorization, are not medically necessary or are not covered because they are a contract exclusion can be found in the Coding section of the Genetic Testing Services or Proprietary Laboratory Analyses policies. Please refer to the appropriate Benefit Booklet to determine whether the member's plan has customized benefit coverage. Please refer to the list of Related Policies for more information.

Note: Laboratories are not allowed to obtain clinical authorization or participate in the authorization process on behalf of the ordering physician. Only the ordering physician shall be involved in the authorization, appeal or other administrative processes related to prior authorization/medical necessity.

In no circumstance shall a laboratory or a physician/provider use a representative of a laboratory or anyone with a relationship to a laboratory and/or a third party to obtain authorization on behalf of the ordering physician, to facilitate any portion of the authorization process or any subsequent appeal of a claim where the authorization process was not followed and/or a denial for clinical appropriateness was issued, including any element of the preparation of necessary documentation of clinical appropriateness. If a laboratory or a third party is found to be supporting any portion of the authorization process, BCBSRI (Blue Cross & Blue Shield of Rhode Island) will deem the action a violation of this policy and severe action will be taken up to and including termination from the BCBSRI provider network. If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND

Colorectal Cancer

For patients at average risk for colorectal cancer (CRC), organizations such as the U.S. Preventive Services Task Force have recommended several options for colon cancer screening. The diagnostic performance characteristics of the currently accepted screening options (ie, colonoscopy, sigmoidoscopy, fecal tests) have been established using colonoscopy as the criterion standard. Modeling studies and clinical trial evidence on some of the screening modalities have allowed some confidence in the effectiveness of several cancer screening modalities. The efficacy of these tests is supported by numerous studies evaluating the diagnostic characteristics of the test for detecting cancer and cancer precursors along with a well-developed body of knowledge on the natural history of the progression of cancer precursors to cancer. Early detection of CRC reduces disease-related mortality, yet many individuals do not undergo recommended screening with fecal

occult blood test or colonoscopy. A simpler screening blood test may have the potential to encourage screening and decrease mortality if associated with increased screening compliance.

SEPT9 Methylated DNA

ColoVantage (various manufacturers) blood tests for serum Septin9 (*SEPT9*) methylated DNA are offered by several laboratories (ARUP Laboratories, Quest Diagnostics, Clinical Genomics). Epi proColon (Epigenomics) received U.S. Food and Drug Administration (FDA) approval in April 2016. Epigenomics has licensed its Septin 9 DNA biomarker technology to Polymedco and LabCorp. ColoVantage and Epi proColon are both polymerase chain reaction (PCR) assays; however, performance characteristics vary across tests, presumably due to differences in methodology (eg, DNA preparation, PCR primers, probes).

Gene Expression Profiling

ColonSentry (Stage Zero Life Sciences) is a PCR assay that uses a blood sample to detect the expression of 7 genes found to be differentially expressed in CRC patients compared with controls: *ANXA3*, *CLEC4D*, *TNFAIP6*, *LMNB1*, *PRRG4*, *VNN1*, and *IL2RB*. The test is intended to stratify average-risk adults who are non-compliant with colonoscopy and/or fecal occult blood testing. Because of its narrow focus, the test is not expected to alter clinical practice for patients who comply with recommended screening schedules.

BeScreened-CRC (Beacon Biomedical) is a PCR assay that uses a blood sample to detect the expression of 3 protein biomarkers: teratocarcinoma derived growth factor-1 (TDGF-1, Cripto-1); carcinoembryonic antigen, a well-established biomarker associated with CRC; and an extracellular matrix protein involved in early-stage tumor stroma changes.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Genetic tests evaluated in this evidence review are available under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed under the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. FDA has chosen not to require any regulatory review of these tests.

The Epi proColon test is the only *SEPT9* DNA test that has received FDA approval. It was approved in 2016 for use in average-risk patients who decline other screening methods.

U.S. Multi-Society Task Force on Colorectal Cancer

The U.S. Multi-Society Task Force on Colorectal Cancer represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. In 2017, the Task Force's clinical guidelines stated that the advantage of *SEPT9* assays for CRC screening is convenience. The disadvantage is "markedly inferior performance characteristics compared with FIT [fecal immunochemical test]." The guidelines also stated that the best frequency for performing the test is unknown and that the task force recommended not using *SEPT9* assays for CRC screening.

U.S. Preventive Services Task Force Recommendations

In 2021, the U.S. Preventive Services Task Force (USPSTF) updated its recommendations for CRC screening in adults. It recommended screening for CRC starting at age 45 years and continuing until age 85 years. However, conclusions regarding the level of certainty and net benefit with screening varied by age groups. The USPSTF provided a Grade A recommendation for screening in adults aged 50 to 75 years (based on high certainty of a substantial net benefit), a Grade B recommendation for screening in adults aged 45 to 49 years (based on moderate certainty of a moderate net benefit), and a Grade C recommendation for selective screening in adults aged 76 to 85 years (based on moderate certainty of a small net benefit). The guideline states that "because of limited available evidence, the USPSTF recommendation does not include serum tests, urine tests, or capsule endoscopy for colorectal cancer screening." The evidence review supporting the recommendations included a search for studies of serum-based tests (eg, methylated *SEPT9* DNA tests) but concluded that the strength of evidence was low, based on a single case-control study.

For individuals who are being screened for CRC who receive serologic molecular or genetic screening for CRC, the evidence includes case-control, cross-sectional, and prospective diagnostic accuracy studies along with systematic reviews of those studies. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, change in disease status, and morbid events. The evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening (PRESEPT) prospective study estimated the sensitivity and specificity of Epi proColon detection of invasive adenocarcinoma at 48% and 92%, respectively. Other studies were generally low to fair quality. In systematic reviews, sensitivity ranged from 62% to 71% and pooled specificity ranged from 91% to 93%. Based on results from these studies, the clinical validity of Septin9 (SEPT9) methylated DNA screening is limited by the low sensitivity of the test. Optimal intervals for retesting are not known. Sensitivity in the 2 cross-sectional studies of ColonSentry ranged from 61% to 72% and specificity for detecting CRC were 70% to 77%. Based on results from these studies, the clinical validity of gene expression screening is limited by low sensitivity and low specificity. No published peer-reviewed evidence was identified for BeScreened-CRC. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Medicare Advantage Plans

Blood-based Biomarker Tests

Blood-based DNA testing detects molecular markers of altered DNA that are contained in the cells shed into the blood by colorectal cancer and pre-malignant colorectal epithelial neoplasia. A blood-based biomarker test is covered as an appropriate colorectal cancer screening test. Please refer to the Preventive Services for Medicare Advantage Plans.

The currently available Epi proColon® test does not meet the criteria for an appropriate blood-based biomarker CRC screening test. Based on the evidence at this time, the Epi proColon® test will not be covered.

CODING

Medicare Advantage Plans and Commercial Products

The following code is covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

G0327 Colorectal cancer screening; blood-based biomarker

The following code(s) are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products:

81327 SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis

This code can be used for BeScreened™–CRC test

0163U Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas

CPT codes have not been assigned to all of the tests addressed in this policy. Therefore, an Unlisted code(s) should be used.

RELATED POLICIES

Biomarker Testing Mandate

Genetic Testing Services Policy

Medicare Advantage Plans National and Local Coverage Determinations

Preventive Services for Medicare Advantage Plans

Proprietary Laboratory Analyses (PLA) and Multianalyte Assays with Algorithmic Analyses (MAAA)

PUBLISHED

Provider Update, December 2025

Provider Update, December 2024

Provider Update, July/November 2023

Provider Update, October 2022

Provider Update, November 2021

REFERENCES

1. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD): Colorectal Cancer Screening Tests (210.3) <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=281&ncdver=7>
2. Centers for Medicare and Medicaid Services (CMS). Local Coverage Article: Billing and Coding: Molecular Pathology Procedures (A56199) <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56199&ver=105&keyword=&keywordType=starts&areaId=all&doctType=6,3,5,1,F,P&contractOption=all&hcpcsOption=code&hcpcsStartCode=81327&hcpcsEndCode=81327&sortBy=title&bc=1>
3. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000); <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=35000&ver=144>
4. Centers for Medicare and Medicaid Services (CMS). (n.d.). *MLN006559 – Medicare Preventive Services*. Retrieved September 26, 2025, from https://www.cms.gov/medicare/prevention/prevntiongeninfo/medicare-preventive-services/mps-quickreferencechart-1.html#COLO_CAN
5. Yip KT, Das PK, Suria D, et al. A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. *J Exp Clin Cancer Res*. Sep 16 2010; 29(1): 128. PMID 20846378
6. Chao S, Ying J, Liew G, et al. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study. *J Exp Clin Cancer Res*. Jul 23 2013; 32(1): 44. PMID 23876008
7. Beacon Biomedical. Non-Clinical Verification and Clinical Validation of BeScreened-CRC, a Blood-Based In Vitro Diagnostic Multivariate Index Assay for the Detection of Colorectal Cancer in Screening Non-Compliant Patients. 2017. https://static1.squarespace.com/static/5b8832f8f2e6b1941b7c53ac/t/5df286f293135176b05b5edb/1576175349526/BeScreened-CRC+White+Paper_2017_+201901R1.pdf Accessed May 22, 2024.
8. U.S. Preventive Services Task Force. Colorectal cancer: screening. Updated May 18, 2021; <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening>. Accessed May 21, 2024.
9. Nian J, Sun X, Ming S, et al. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis. *Clin Transl Gastroenterol*. Jan 19 2017; 8(1): e216. PMID 28102859
10. Song L, Jia J, Peng X, et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. *Sci Rep*. Jun 08 2017; 7(1): 3032. PMID 28596563
11. Hariharan R, Jenkins M. Utility of the methylated SEPT9 test for the early detection of colorectal cancer: a systematic review and meta-analysis of diagnostic test accuracy. *BMJ Open Gastroenterol*. 2020; 7(1): e000355. PMID 32128229
12. Li B, Gan A, Chen X, et al. Diagnostic Performance of DNA Hypermethylation Markers in Peripheral Blood for the Detection of Colorectal Cancer: A Meta-Analysis and Systematic Review. *PLoS One*. 2016; 11(5): e0155095. PMID 27158984
13. Yan S, Liu Z, Yu S, et al. Diagnostic Value of Methylated Septin9 for Colorectal Cancer Screening: A Meta-Analysis. *Med Sci Monit*. Sep 25 2016; 22: 3409-3418. PMID 27665580
14. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. *Gut*. Feb 2014; 63(2): 317-25. PMID 23408352
15. Song L, Wang J, Wang H, et al. The quantitative profiling of blood mSEPT9 determines the detection performance on colorectal tumors. *Epigenomics*. Dec 2018; 10(12): 1569-1583. PMID 30426784

16. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. *Int J Cancer*. Mar 01 2010; 126(5): 1177-86. PMID 19795455
17. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*. Jul 2018; 68(4): 250-281. PMID 29846947
18. Shaukat A, Kahi CJ, Burke CA, et al. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. *Am J Gastroenterol*. Mar 01 2021; 116(3): 458-479. PMID 33657038
19. Qaseem A, Crandall CJ, Mustafa RA, et al. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. *Ann Intern Med*. Nov 05 2019; 171(9): 643-654. PMID 31683290
20. Qaseem A, Harrod CS, Crandall CJ, et al. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians (Version 2). *Ann Intern Med*. Aug 2023; 176(8): 1092-1100. PMID 37523709
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: colorectal cancer screening. Version 1.2024. https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Accessed May 19, 2024.
22. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. *Am J Gastroenterol*. Jul 2017; 112(7): 1016-1030. PMID 28555630
23. Davidson KW, Barry MJ, Mangione CM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. May 18 2021; 325(19): 1965-1977. PMID 34003218
24. Lin JS, Perdue LA, Henrikson NB, et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. May 18 2021; 325(19): 1978-1998. PMID 34003220

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

